2023 Form 5500 filing — Iovance Biotherapeutics, Inc. 401(K) Plan
Plain-English filing summary
According to public Form 5500 filings published through the U.S. Department of Labor (DOL) Employee Benefits Security Administration (EBSA) via the EFAST2 system, this is the 2023 Form 5500 filing (EFAST2 acknowledgement 20240830110452NAL0014435873001) for Iovance Biotherapeutics, Inc. 401(K) Plan, reported by Iovance Biotherapeutics, Inc. under EIN 75-3254381 and plan number 001. It reports 586 participants. Attached schedules in the loaded dataset include Schedule H (large plan financials), Schedule C (service provider compensation).
- EFAST2 acknowledgement
- 20240830110452NAL0014435873001
- Filing year
- 2023
- Form type
- 2
- Plan sponsor
- Iovance Biotherapeutics, Inc.
- EIN
- 75-3254381
- Plan number
- 001
- Location
- San Carlos, CA
- Participants
- 586
- Schedules available
- Schedule H, Schedule C
- Received date
- not reported in the loaded dataset
Reported financial snapshot (2023)
- Total assets (EOY)
- $42,588,709
- Total liabilities (EOY)
- $0
- Net assets (EOY)
- $42,588,709
- Employer contributions
- $4,031,098
- Participant contributions
- $8,359,487
- Total income / additions
- $19,387,899
- Benefits paid
- $2,354,630
- Administrative expenses
- $94,745
- Total expenses
- $2,466,708
- Net increase / (decrease)
- $16,921,191
- Schedule source
- Schedule H
Reported service provider compensation (Schedule C)
| Provider | Service | Direct comp. | Indirect comp. |
|---|---|---|---|
| Fidelity Investments Institutional | RECORDKEEPER | $60,777 | $0 |
| Kestra Investment Services LLC | ADVISOR | $29,968 | not reported in the loaded dataset |